Firefly Neuroscience (AIFF) EBIT (2010 - 2026)

Firefly Neuroscience's EBIT history runs 16 years deep, the most recent figure standing at -$2.0 million for Q1 2026.

• In Q1 2026, EBIT rose 2.66% year-over-year to -$2.0 million; the TTM figure through Mar 2026 stood at -$8.8 million (down 1.36% YoY), while the FY2025 annual figure was -$8.9 million, up 11.92% from the prior year.
• EBIT was -$2.0 million for Q1 2026 at Firefly Neuroscience, up from -$2.5 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $793000.0 in Q4 2023 to a low of -$4.3 million in Q3 2024.
• Historically, EBIT has averaged -$1.5 million across 5 years, with a median of -$1.4 million in 2022.
• The sharpest annual moves came in 2022 and 2023: EBIT tumbled 3062.76% in 2022, then soared 178.32% in 2023.
• A 5-year view of EBIT shows it stood at -$1.0 million in 2022, then surged by 178.32% to $793000.0 in 2023, then plunged by 638.21% to -$4.3 million in 2024, then surged by 41.4% to -$2.5 million in 2025, then climbed by 19.63% to -$2.0 million in 2026.
• The last three EBIT figures came in at -$2.0 million (Q1 2026), -$2.5 million (Q4 2025), and -$2.7 million (Q3 2025), per Business Quant data.